The latest biotech news

crispr therapeutics vertex beta thalassemia

News and Trends 19 Nov 2019

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

CRISPR Therapeutics and its US partner Vertex Pharmaceuticals have released the first clinical results for a cell therapy made using the gene editing tool CRISPR/Cas9 in patients with genetic blood disorders. The interim results concern two patients enrolled in different phase I/II clinical trials testing the same therapy in two blood disorders: transfusion-dependent beta-thalassemia and […]

November 19, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 19 Nov 2019

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […]

November 19, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […]

November 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Nov 2019

UK Spinout Secures Over €3M to Develop Novel Anticoagulants

LUNAC Therapeutics has spun out of the University of Leeds with €3.09M of funding from the university and the VC firm Epidarex Capital for the development of anticoagulants with a lower risk for bleeding than those currently available. The new anticoagulants will target activated factor XII, a protein which company founders Helen Philippou and Richard […]

November 15, 2019 - 2 minutesmins - By External Contributor

News and Trends 14 Nov 2019

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […]

November 14, 2019 - 2 minutesmins - By Jonathan Smith

bone marrow transplant blood cancer kiadis pharma cell therapy

News and Trends 13 Nov 2019

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood cancer, laid off half of its workforce, and switched focus to other, less advanced cell therapy programs. The abandoned phase III trial was testing Kiadis Pharma’s lead cell therapy for the treatment of graft-versus-host disease, a complication of stem cell […]

November 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy […]

November 12, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 11 Nov 2019

Argenx Raises Whopping €502M in Global Offering

The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 8 Nov 2019

EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience

An EU research project has launched with the aim of bringing mRNA treatments to a wider range of patients and diseases. The EXPERT – Expanding Platforms for Efficacious mRNA Therapeutics – project is a collaboration among academics and industry experts from 11 countries who will work on a novel delivery system for messenger (m)RNA therapeutics […]

November 8, 2019 - 4 minutesmins - By External Contributor

centogene rare diseases diagnostic ipo nasdaq

News and Trends 7 Nov 2019

€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics

The German company Centogene has raised €50.6M ($56M) in an IPO on the Nasdaq Stock Exchange to fund the development of diagnostics technology that could improve the treatment of rare diseases. The fundraise fell under Centogene’s target value of €54M ($60M). A part of the proceeds will fuel the development of biomarkers that Centogene will […]

November 7, 2019 - 2 minutesmins - By Jonathan Smith

cancer vaccine virus ervaxx cell therapy

News and Trends 6 Nov 2019

UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines

The London-based startup Ervaxx has launched with a €15.8M Series A round to develop cancer vaccines and cell therapies that target ‘dark antigens’ — normally silent genes in the genome that are expressed in cancer cells. Ervaxx’s Series A round was funded by the transatlantic venture capital firm SV Health Investors, as well as an […]

November 6, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Nov 2019

UK Scientists Speed up Brain Cancer Diagnosis with AI

A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people […]

November 5, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

UK Spinout Secures Over €3M to Develop Novel Anticoagulants

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

Argenx Raises Whopping €502M in Global Offering

EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience

€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics

UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines

UK Scientists Speed up Brain Cancer Diagnosis with AI

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!